Ziconotide: A new option for refractory pain

Drugs of Today

Volumn 42, Issue 6, 2006, Pages 369-378

  Prommer, Eric ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; ANXIOLYTIC AGENT; ASPARTATE AMINOTRANSFERASE; BACLOFEN; BILIRUBIN; CAPSAICIN; CARBAMAZEPINE; CREATININE; DANTROLENE; DIAZEPAM; GAMMA GLUTAMYLTRANSFERASE; LACTATE DEHYDROGENASE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID; NEUROLEPTIC AGENT; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA CONOTOXIN MVIIA; OMEGA CONOTOXIN MVIIC; OPIATE; OPIATE ANTAGONIST; PHOSPHOTRANSFERASE; TRICYCLIC ANTIDEPRESSANT AGENT; VANILLOID RECEPTOR 1; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AGITATION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALERTNESS; AMNESIA; ANTINOCICEPTION; ATAXIA; AUDITORY HALLUCINATION; BILIRUBIN BLOOD LEVEL; BLURRED VISION; BRADYCARDIA; CHRONIC PAIN; CLINICAL TRIAL; CONFUSION; CONJUNCTIVAL HYPEREMIA; CONSTIPATION; COST BENEFIT ANALYSIS; COUGHING; CREATININE BLOOD LEVEL; DELIRIUM; DIARRHEA; DISORIENTATION; DIZZINESS; DOSE RESPONSE; DRUG ACTIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG OVERDOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSMETRIA; EMOTION; EXCITABILITY; EYE DISEASE; FEVER; HUMAN; HYPERPOLARIZATION; KIDNEY DISEASE; LACTATE DEHYDROGENASE BLOOD LEVEL; LIMB PAIN; LIVER TOXICITY; MEMBRANE DEPOLARIZATION; MENINGITIS; MICTURITION; MYOCLONUS; NAUSEA; NERVE CELL PLASTICITY; NEUROTOXICITY; NOCICEPTION; NOSE CONGESTION; NYSTAGMUS; ORTHOSTATIC HYPOTENSION; OSCILLOPSIA; PARANOIA; RASH; REVIEW; RHINITIS; SEDATION; SENSORY NERVE; SIDE EFFECT; SINUS BRADYCARDIA; SNAIL; SNEEZING; SOMNOLENCE; STIMULUS RESPONSE; SYNAPTIC TRANSMISSION; SYNCOPE; T WAVE; TACHYCARDIA; UROGENITAL TRACT DISEASE; VASODILATATION; VESTIBULAR DISORDER; VISUAL HALLUCINATION;

ANALGESICS, NON-NARCOTIC; ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; OMEGA-CONOTOXINS; PAIN;

EID: 33746261240     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2006.42.6.973534     Document Type: Review

References (29)

1. Jain, K.K. An evaluation of intrathecal ziconotide for the treatment of chronic pain. Expert Opin Investig Drugs 2000, 9: 2403-10.
2. Wang, Y.X., Gao, D., Pettus, M., Phillips, C., Bowersox, S.S. Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats. Pain 2000, 84: 271-81.
3. Atanassoff, P.G., Hartmannsgruber, M.W., Thrasher, J. et al. Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain. Reg Anesth Pain Med 2000, 25: 274-8.
4. Staats, P.S., Yearwood, T., Charapata, S.G. et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: A randomized controlled trial. JAMA 2004, 291: 63-70.
5. Lee, Y., Lee, C.H., Oh, U. Painful channels in sensory neurons. Mol Cells 2005, 20: 315-24.
6. Akopian, A.N., Sivilotti, L., Wood, J.N. A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature 1996, 379: 257-62.
7. Cummins, T.R., Waxman, S.G. Downregulation of tetrodotoxin-resistant sodium currents and upregulation of a rapidly repriming tetrodotox-in-sensitive sodium current in small spinal sensory neurons after nerve injury. J Neurosci 1997, 17: 3503-14.
8. Tominaga, M., Caterina, M.J., Malmberg, A.B. et al. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 1998, 21: 531-43.
9. White, D.M., Cousins, M.J. Effect of subcutaneous administration of calcium channel blockers on nerve injury-induced hyperalgesia. Brain Res 1998, 801: 50-8.
10. Luchian, T. The influence exerted by the beta(3) subunit on MVIIA omega-conotoxin binding to neuronal N-type calcium channels. Biochim Biophys Acta 2001, 1512: 329-34.
11. Wermeling, D.P. Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain. Pharmacotherapy 2005, 25: 1084-94.
12. Doggrell, S.A. Intrathecal ziconotide for refractory pain. Expert Opin Investig Drugs 2004, 13: 875-7.
13. Gaur, S., Newcomb, R., Rivnay, B. et al. Calcium channel antagonist peptides define several components of transmitter release in the hippocampus. Neuropharmacology 1994, 33: 1211-9.
14. McGuire, D., Bowersox, S., Fellmann, J.D., Luther, R.R. Sympatholysis after neuron-specific, N-type, voltage-sensitive calcium channel blockade: First demonstration of N-channel function in humans. J Cardiovasc Pharmacol 1997, 30: 400-3.
15. Penn, R.D., Paice, J.A. Adverse effects associated with the intrathecal administration of ziconotide. Pain 2000, 85: 291-6.
16. Wermeling, D., Drass, M., Ellis, D. et al. Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients. J Clin Pharmacol 2003, 43: 624-36.
17. Product information, Prialt™, Ziconotide Intrathecal Infusion. Elan Pharmaceuticals, Inc., San Diego 2004.
18. Bowersox, S.S., Gadbois, T., Singh, T., Pettus, M., Wang, Y.X., Luther, R.R. Selective N-type neuronal voltage-sensitive calcium channel blocker, SNX-111, produces spinal antinociception in rat models of acute, persistent and neuropathic pain. J Pharmacol Exp Ther 1996, 279: 1243-9.
19. Yamamoto, T., Sakashita, Y. Differential effects of intrathecally administered N- and P-type voltage-sensitive calcium channel blockers upon two models of experimental mononeuropathy in the rat. Brain Res 1998, 794: 329-32.
20. Malmberg, A.B., Yaksh, T.L. Effect of continuous intrathecal infusion of omega-conopeptides, N-type calcium-channel blockers, on behavior and antinociception in the formalin and hot-plate tests in rats. Pain 1995, 60: 83-90.
21. Bowersox, S.S., Luther, R. Pharmacotherapeutic potential of omega-conotoxin MVIIA (SNX-111), an N-type neuronal calcium channel blocker found in the venom of Conus magus. Toxicon 1998, 36: 1651-8.
22. Vanegas, H., Schaible, H. Effects of antagonists to high-threshold calcium channels upon spinal mechanisms of pain, hyperalgesia and allodynia. Pain 2000, 85: 9-18.
23. Brose, W.G., Gutlove, D.P., Luther, R.R., Bowersox, S.S., McGuire, D. Use of intrathecal SNX-111, a novel, N-type, voltage-sensitive, calcium channel blocker, in the management of intractable brachial plexus avulsion pain. Clin J Pain 1997, 13: 256-9.
24. Ridgeway, B., Wallace, M., Gerayli, A. Ziconotide for the treatment of severe spasticity after spinal cord injury. Pain 2000, 85: 287-9.
25. Levin, T., Petrides, G., Weiner, J., Saravay, S., Multz, A.S., Bailine, S. Intractable delirium associated with ziconotide successfully treated with electroconvulsive therapy. Psychosomatics 2002, 43: 63-6.
26. Jeret, J.S. Diltiazem-induced myoclonus. Neurology 2002, 59: 962.
27. Papadopoulos, J., O'Neil, M.G. Utilization of a glucagon infusion in the management of a massive nifedipine overdose. J Emerg Med 2000, 18: 453-5.
28. Drug Topics Red Book, 108th ed. Thomson Scientific and Healthcare, Stamford 2004, 2006.
29. Hassenbusch, S.J., Paice, J.A., Patt, R.B. et al. Clinical realities and economic considerations: Economics of intrathecal therapy. J Pain Symptom Manage 1997, 3 (Suppl.): S36-S48.